OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Eligibility Rates among Racially and Ethnically Diverse US Participants in Phase 2 and Phase 3 Placebo‐Controlled, Double‐Blind, Randomized Trials of Lecanemab and Elenbecestat in Early Alzheimer Disease
Joshua D. Grill, Charlene Flournoy, Shobha Dhadda, et al.
Annals of Neurology (2023) Vol. 95, Iss. 2, pp. 288-298
Open Access | Times Cited: 17
Joshua D. Grill, Charlene Flournoy, Shobha Dhadda, et al.
Annals of Neurology (2023) Vol. 95, Iss. 2, pp. 288-298
Open Access | Times Cited: 17
Showing 17 citing articles:
Treatment of Alzheimer Disease
David Geldmacher
CONTINUUM Lifelong Learning in Neurology (2024) Vol. 30, Iss. 6, pp. 1823-1844
Closed Access | Times Cited: 19
David Geldmacher
CONTINUUM Lifelong Learning in Neurology (2024) Vol. 30, Iss. 6, pp. 1823-1844
Closed Access | Times Cited: 19
Biomarker-guided decision making in clinical drug development for neurodegenerative disorders
Jeffrey L. Cummings, Charlotte E. Teunissen, Brian Fiske, et al.
Nature Reviews Drug Discovery (2025)
Closed Access | Times Cited: 3
Jeffrey L. Cummings, Charlotte E. Teunissen, Brian Fiske, et al.
Nature Reviews Drug Discovery (2025)
Closed Access | Times Cited: 3
Updated Appropriate Use Criteria for Amyloid and Tau PET: A Report from the Alzheimer’s Association and Society for Nuclear Medicine and Molecular Imaging Workgroup
Gil D. Rabinovici, D. S. Knopman, Javier Arbizu, et al.
Journal of Nuclear Medicine (2025), pp. jnumed.124.268756-jnumed.124.268756
Closed Access | Times Cited: 2
Gil D. Rabinovici, D. S. Knopman, Javier Arbizu, et al.
Journal of Nuclear Medicine (2025), pp. jnumed.124.268756-jnumed.124.268756
Closed Access | Times Cited: 2
Maximizing the benefit and managing the risk of anti-amyloid monoclonal antibody therapy for Alzheimer's disease: Strategies and research directions
Jeffrey L. Cummings
Neurotherapeutics (2025), pp. e00570-e00570
Open Access | Times Cited: 2
Jeffrey L. Cummings
Neurotherapeutics (2025), pp. e00570-e00570
Open Access | Times Cited: 2
Racial and ethnic differences in plasma biomarker eligibility for a preclinical Alzheimer's disease trial
Doris P. Molina‐Henry, Rema Raman, Andy Liu, et al.
Alzheimer s & Dementia (2024) Vol. 20, Iss. 6, pp. 3827-3838
Open Access | Times Cited: 6
Doris P. Molina‐Henry, Rema Raman, Andy Liu, et al.
Alzheimer s & Dementia (2024) Vol. 20, Iss. 6, pp. 3827-3838
Open Access | Times Cited: 6
Pathways to personalized medicine—Embracing heterogeneity for progress in clinical therapeutics research in Alzheimer's disease
Steven E. Arnold, Bradley T. Hyman, Rebecca A. Betensky, et al.
Alzheimer s & Dementia (2024) Vol. 20, Iss. 10, pp. 7384-7394
Open Access | Times Cited: 4
Steven E. Arnold, Bradley T. Hyman, Rebecca A. Betensky, et al.
Alzheimer s & Dementia (2024) Vol. 20, Iss. 10, pp. 7384-7394
Open Access | Times Cited: 4
Distinct medical and substance use histories associate with cognitive decline in Alzheimer's disease
Clayton Mansel, Diego R. Mazzotti, Ryan Townley, et al.
Alzheimer s & Dementia (2025) Vol. 21, Iss. 3
Open Access
Clayton Mansel, Diego R. Mazzotti, Ryan Townley, et al.
Alzheimer s & Dementia (2025) Vol. 21, Iss. 3
Open Access
Generalizability of trial criteria on amyloid-lowering therapy against Alzheimer’s disease to individuals with mild cognitive impairment or early Alzheimer’s disease in the general population
Jacqueline J. Claus, Ilse vom Hofe, Annekee van Ijlzinga Veenstra, et al.
European Journal of Epidemiology (2025)
Open Access
Jacqueline J. Claus, Ilse vom Hofe, Annekee van Ijlzinga Veenstra, et al.
European Journal of Epidemiology (2025)
Open Access
Will Vietnamese American communities benefit from new Alzheimer's disease treatments?
Kim Hoang, Oanh L. Meyer, Joshua D. Grill
(2025) Vol. 1, Iss. 1
Open Access
Kim Hoang, Oanh L. Meyer, Joshua D. Grill
(2025) Vol. 1, Iss. 1
Open Access
Increasing representation of Asian American, Native Hawaiian, and Pacific Islander communities in aging, dementia, and caregiving research: An update from the CARE registry
Joshua D. Grill, Janice Y. Tsoh, Bora Nam, et al.
Alzheimer s & Dementia (2025) Vol. 21, Iss. 4
Open Access
Joshua D. Grill, Janice Y. Tsoh, Bora Nam, et al.
Alzheimer s & Dementia (2025) Vol. 21, Iss. 4
Open Access
Cognivue Clarity characterizes mild cognitive impairment and Alzheimer’s disease in biomarker confirmed cohorts in the Bio-Hermes Study
James E. Galvin, Michael J. Kleiman, Paul W. Estes, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 2
James E. Galvin, Michael J. Kleiman, Paul W. Estes, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 2
Relationship between Plasma P-Tau217 and Amyloid PET in Racial and Ethnic Underrepresented Groups (RE-URG) Compared with Non RE-URG in LEARN and A4
Doris P. Molina‐Henry, Oliver Langford, M C Donohue, et al.
The Journal of Prevention of Alzheimer s Disease (2024)
Open Access | Times Cited: 1
Doris P. Molina‐Henry, Oliver Langford, M C Donohue, et al.
The Journal of Prevention of Alzheimer s Disease (2024)
Open Access | Times Cited: 1
Baseline levels and longitudinal changes in plasma Aβ42/40 among Black and white individuals
Chengjie Xiong, Jingqin Luo, David A. Wolk, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 1
Chengjie Xiong, Jingqin Luo, David A. Wolk, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 1
Generalizability of trial criteria on amyloid-lowering therapy against Alzheimer’s disease to individuals with MCI or early AD in the general population
Jacqueline J. Claus, Ilse vom Hofe, Annekee van Ijlzinga Veenstra, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Jacqueline J. Claus, Ilse vom Hofe, Annekee van Ijlzinga Veenstra, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Evaluating Lecanemab Eligibility for Patients in Skilled Nursing Facilities With Alzheimer Disease or Mild Cognitive Impairment
Elizabeth G. Stettenbauer, Sarah D. Berry, Yoojin Lee, et al.
Journal of the American Medical Directors Association (2024) Vol. 25, Iss. 11, pp. 105192-105192
Closed Access
Elizabeth G. Stettenbauer, Sarah D. Berry, Yoojin Lee, et al.
Journal of the American Medical Directors Association (2024) Vol. 25, Iss. 11, pp. 105192-105192
Closed Access
Cognivue Clarity ® Characterizes Mild Cognitive Impairment and Alzheimer’s Disease in Biomarker Confirmed Cohorts in the Bio-Hermes Study
James E. Galvin, Michael J. Kleiman, Paul W. Estes, et al.
Research Square (Research Square) (2024)
Closed Access
James E. Galvin, Michael J. Kleiman, Paul W. Estes, et al.
Research Square (Research Square) (2024)
Closed Access
Distinct Medical and Substance Use Histories Associate with Cognitive Decline in Alzheimer's Disease
Clayton Mansel, Diego R. Mazzotti, Ryan Townley, et al.
(2024)
Open Access
Clayton Mansel, Diego R. Mazzotti, Ryan Townley, et al.
(2024)
Open Access
